Virbac edges up on 'solid' H1 sales

Virbac SA

17/07/2025 08:15

** Shares in French animal drugs company Virbac VIRB.PA edge up about 2% following "solid" H1 sales, paring earlier gains of as much as 3.45%

** Virbac reports H1 consolidated revenue up by 5.6% to 738.3 million euros ($854.73 million), and maintains FY guidance

** Portzamparc analyst Gaétan Calabro says the report exceeded the brokerage's estimates and was "particularly solid"

** "(The) publication reinforces the group's guidance, knowing that the second half of the year will have a more favourable base effect in organic terms", the analyst says in a note

** Calabro reiterates "buy" rating with PT of 428.5 euros, saying the current valuation represents a "very good entry point for the stock"

($1 = 0.8638 euros)

 (Reporting by Mateusz Rabiega)

 ((Mateusz.rabiega@thomsonreuters.com))